Drug Database
AD

adenovirus vaccines

✓ Approved

Teva Pharmaceutical Industries Ltd. · 疫苗 · 疫苗

什么是 adenovirus vaccines?

adenovirus vaccines 是一种疫苗,由Teva Pharmaceutical Industries Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Teva Pharmaceutical Industries Ltd.
药物类别疫苗, 大分子
给药途径Oral (PO)
状态Approved

治疗适应症

adenovirus vaccines 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAdenovirus infection✓ Approved

相关研究文献

PubMedMicrobiology spectrum2026-10-26

Dengue virus-2 triggers Epstein-Barr virus replication in primary B cells by co-opting the IRE1-XBP1 signaling axis.

Deng Xiaomei X, Deng Rongping R, Guo Xiuyan X, Li Jialing J et al.

The intricate interplay between co-infecting viral pathogens within a host can significantly influence disease outcomes. Dengue virus (DENV), a globally prevalent arbovirus from the Flaviviridae family, and Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, share extensive geographical overlap, yet their potential interactions remain largely uncharacterized. This study elucidates a novel molecular mechanism whereby DENV-2 infection triggers disruption of EBV latency. We systematically demonstrate that DENV-2 infection consistently induces EBV lytic gene expression and viral replication in diverse cellular contexts, including epithelial cell lines and, critically, in primary human B lymphocytes-the principal reservoir of latent EBV. Mechanistically, we establish that the substantial burden of DENV-2 protein synthesis and replication induces profound endoplasmic reticulum (ER) stress, activating the unfolded protein response (UPR). Through pharmacological inhibition and genetic knockdown, we dissect the three UPR branches and identify the IRE1-XBP1 signaling axis as the indispensable pathway for this phenomenon. DENV-2 infection promotes the endoribonuclease activity of IRE1, leading to the unconventional splicing of XBP1 mRNA into its transcriptionally active isoform, XBP1s. Depletion of IRE1 or XBP1 attenuated DENV-induced BZLF1 expression, whereas ectopic XBP1s expression increased BZLF1 transcription. Our findings delineate a precise virus-host-virus signaling model in which an acute RNA virus engages a cellular stress pathway to promote entry into the EBV lytic program and viral genome amplification. This provides a new paradigm for understanding the pathobiology of dengue fever and the complex dynamics of the human virome.IMPORTANCEThis research uncovers a previously unrecognized molecular dialog between two of the world's most common viral pathogens. By demonstrating that dengue virus infection can awaken dormant Epstein-Barr virus, this study provides a mechanistic basis for the long-suspected but poorly understood complications arising from viral co-infections. We pinpoint a specific cellular stress pathway, the IRE1-XBP1 axis of the unfolded protein response (UPR), as the critical molecular switch. This discovery is significant because it not only explains how an acute viral illness can trigger the reactivation of a latent, potentially oncogenic virus but also opens new avenues for therapeutic intervention. Understanding this intricate interplay could lead to novel strategies for managing severe dengue and other diseases where viral co-infection is a contributing factor to pathogenesis.

PMID 42929539
阅读全文 →
PubMedJournal of virology2026-10-26

Novel roles of the Epstein-Barr virus BRRF1 protein in post-transcriptional RNA regulation.

Campbell Ashley M AM, Shire Kathy K, Ho Talia T, Sinay Zora Z et al.

In lytic infection, Epstein-Barr virus (EBV) proteins manipulate cellular processes in multiple ways to facilitate virion production and overcome host antiviral responses. Here, we screened a library of EBV lytic proteins for those that manipulate or localize to cellular processing bodies (PBs), known to play important roles in RNA surveillance and miRNA-mediated translational control. One EBV protein, BRRF1, was identified that partially localized to PBs, and affinity purification-mass spectrometry experiments showed that it interacted with the CCR4-NOT complex-a known component of PBs with multiple roles in post-transcriptional mRNA regulation. The CNOT9 subunit of CCR4-NOT was sufficient to bind BRRF1, and its downregulation diminished BRRF1 interaction with the CNOT1 scaffold protein, indicating its importance in mediating the CCR4-NOT interaction with BRRF1. A BRRF1 double-point mutant was generated that failed to bind CNOT9 or interact with CCR4-NOT and was used to assess the importance of the BRRF1-CCR4-NOT interaction. Luciferase reporter assays identified multiple roles for BRRF1 in post-transcriptional regulation, including polyadenylation-dependent destabilization effects and interference with miRNA function, the latter of which was dependent on BRRF1 binding to CCR4-NOT. In addition, mRNA sequencing experiments comparing cells with and without BRRF1 expression identified multiple transcripts affected by BRRF1, some of which were at least partly dependent on the BRRF1-CCR4-NOT interaction. These include Claudin 6, whose transcripts and protein were downregulated by BRRF1 expressed on its own, as well as in lytic infection. Thus, we have identified multiple roles for BRRF1 in post-transcriptional mRNA regulation, some of which involve interaction with CCR4-NOT. To efficiently generate virions, Epstein-Barr virus (EBV) must manipulate cellular processes to optimize the environment and overcome host antiviral defenses. Through unbiased screening methods, we have identified an EBV protein (BRRF1) that localizes to cellular bodies, which play key roles in mRNA regulation, and that interacts with a cellular complex with multiple critical roles in post-transcriptional mRNA regulation. As expected from these interactions, we found that BRRF1 has multiple previously unknown roles in disrupting mRNA levels and translation. Interestingly, one of the transcripts targeted by BRRF1 is Claudin 6, which has multiple roles in cancers, leading to increased cell proliferation and invasion. Our study provides additional insight into how EBV proteins manipulate cells to promote infection and affect oncogenesis.

PMID 42929519
阅读全文 →
PubMedHuman gene therapy2026-10-26

A Modular Multilocus Engineering Platform for Iterative Prototyping of Oncolytic Adenoviruses.

Dai Zhoutong Z, Yu Hui H, Ye Jiaqi J, Zhang Tianyu T et al.

The development of oncolytic adenovirus type 5 (Ad5) has been constrained by inefficient genome-engineering workflows and a lack of reusable backbones for iterative vector optimization. To address these limitations, we established a modular and reusable engineering workflow for constructing tumor-selective oncolytic Ad5 genomes by integrating BJ5183-mediated homologous recombination with in vitro homology-based DNA assembly. First, the BJ5183-based system enables targeted modification of multiple loci within adenoviral genomes, including the installation of locus-compatible restriction sites such as BstBI, ClaI, and SwaI. Second, an in vitro homology-based DNA assembly module enables insertion of target gene expression cassettes. Third, PacI-linearized genomes are rescued in HEK-293A cells. The resulting backbone retained viral rescue competence and replication selectivity. This platform supports engineering of therapeutic and structural loci within a retained full-length plasmid backbone while allowing the final recombinant plasmid to be sequence-verified before virus rescue. Thus, it provides a practical framework for iterative and parallelized prototyping of armed, capsid-modified, and combinatorial oncolytic Ad5 vectors.

PMID 42929307
阅读全文 →
PubMedGenomics, proteomics & bioinformatics2026-10-26

RNASTOP: A Deep Learning Framework for mRNA Chemical Stability Prediction and Optimization.

Lin Shenggeng S, Chen Junwei J, Sun Heqi H, Zhang Yufang Y et al.

Messenger RNA (mRNA) vaccines offer promising therapeutic potential for combating various diseases, yet their inherent chemical instability hampers long-term efficacy. Although several methods have been developed to predict mRNA degradation, they often suffer from limited accuracy and lack the capability for rational codon optimization. Here, we propose RNASTOP, a novel framework that integrates deep learning with heuristic search to simultaneously predict and optimize mRNA chemical stability. RNASTOP achieves a 13% improvement in accuracy over the top-performing model on the Stanford OpenVaccine competition dataset and demonstrates robust generalization in predicting full-length mRNA degradation. When applied to mRNA codon optimization, RNASTOP reduces the minimum free energy of the varicella-zoster virus vaccine sequence by 75.73% while maintaining high translation efficiency. Overall, RNASTOP serves as a powerful tool for predicting and optimizing mRNA chemical stability, accelerating the development of mRNA therapeutics. The source code of RNASTOP is available at https://github.com/xlab-BioAI/RNASTOP.

PMID 42928593
阅读全文 →
PubMedJournal of clinical laboratory analysis2026-10-26

Comprehensive Performance Verification of the Mindray MN2880 System in Detecting Respiratory Virus Nucleic Acids.

Chen Jinliang J, Zeng Lianying L, Huang Hao H, Chen Peisong P

To verify the clinical performance of the Mindray MN2880 system for simultaneous detection of SARS-CoV-2, influenza A virus (IAV), influenza B virus (IBV), and respiratory syncytial virus (RSV) nucleic acids. According to the CNAS-GL039:2019 and CNAS-GL037:2019 requirements for molecular diagnostic verification, we comprehensively evaluated the Mindray MN2880 multiplex respiratory virus assay across seven critical performance parameters: clinical concordance, limit of detection (LoD), repeatability, precision, cross-reactivity/interference resistance, daily QC, and contamination control. The Mindray MN2880 system demonstrated high diagnostic concordance with the reference method, with total percent agreements of 99.51% (95% CI: 99.00%-99.76%) for SARS-CoV-2, 99.93% (95% CI: 99.60%-99.99%) for IAV, and 100% for both IBV and RSV, and achieved clinically verified limits of detection (LoD: SARS-CoV-2 at 100 copies/mL, IAV/IBV/RSV at 200 copies/mL). Analytical precision was confirmed through 100% detection across negative/low/medium/high concentration panels with ≤ 3% CV for repeatability (Ct values) and ≤ 5% CV for inter-run precision. The assay exhibited 100% specificity against 6 clinically relevant pathogens, including Human Rhinovirus, parainfluenza virus, adenovirus, Mycoplasma pneumoniae, Haemophilus influenzae, and Staphylococcus aureus, with no observed cross-reactivity. Moreover, the MN2880 system demonstrated robust interference resistance (100% detection of weakly-positive samples spiked with seven interferents), stable daily QC performance (100% valid controls across 115 consecutive runs), and 100% contamination prevention. The MN2880 system satisfies key analytical benchmarks required for diagnostic use in respiratory virus multiplex testing, with performance verified against CNAS-GL039:2019 and CNAS-GL037:2019 standards.

PMID 42928602
阅读全文 →
PubMedBiotechnology journal2026-10-26

Cross-Reactive Neutralizing Antibodies Between ZIKV and DENV May Exhibit Serotype Specificity.

Silveira Lucimeire Antonelli da LAD, Saavedra Djairo Pastor DP, Junqueira Isabela Cinquini IC, Dietz Jefferson do Carmo JDC et al.

Dengue virus (DENV) and Zika virus (ZIKV) are public health threats, causing substantial morbidity and mortality worldwide. The co-circulation of DENV and ZIKV complicates prevention and control efforts, highlighting the importance of studying cross-reactive antibodies, vaccines, and immune modulators. This study explores the cross-reactivity and neutralizing capacity of antibodies against DENV elicited by immunization with a ZIKV protein extract. Female isogenic BALB/c mice were immunized with ZIKV protein extract derived from C6/36 cell cultures. Splenic B lymphocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG) to generate hybridomas. The resulting antibodies were assessed using ELISA and plaque reduction neutralization tests (PRNT) against ZIKV and DENV including their structural and nonstructural proteins. Our findings showed that immunization induced a diverse antibody response, including antibodies recognizing epitopes unique to ZIKV as well as epitopes shared with DENV. Notably, neutralizing antibodies targeting conserved epitopes, particularly those shared with DENV-1, were also identified against other DENV serotypes. These results suggest the presence of cross-reactive neutralizing antibody responses between ZIKV and DENV, potentially exhibiting serotype-specific reactivity. Collectively, this study provides experimental evidence of flavivirus cross-reactivity and contributes to a more refined understanding of humoral responses in settings where these viruses co-circulate.

PMID 42928707
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adenovirus vaccines